Skeletal imaging effects of pamidronate therapy in osteosarcoma patients

Pediatric Radiology

Volumn 41, Issue 4, 2011, Pages 451-458

  Price, Anita P ^a   Abramson, Sara J ^a   Hwang, Sinchun ^a   Chou, Alexander ^a   Bartolotta, Roger ^b   Meyers, Paul ^a   Katz, Douglas S ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Children; Metaphyseal bands; Osteosarcoma; Pamidronate; Skeletal changes

Indexed keywords

CISPLATIN; DOXORUBICIN; GADOLINIUM; MEDRONATE TECHNETIUM TC 99M; METHOTREXATE; PAMIDRONIC ACID;

ADOLESCENT; ADULT; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; EPIPHYSIS; FEMALE; FEMUR; FOLLOW UP; GROWTH PLATE; HUMAN; HUMERUS; MAINTENANCE THERAPY; MALE; MAXILLA; METAPHYSIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOSARCOMA; OSTEOSCLEROSIS; PELVIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIB; SCHOOL CHILD; SPINE; STERNUM; THORAX RADIOGRAPHY; TIBIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CISPLATIN; DIPHOSPHONATES; DOXORUBICIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79953820737     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-010-1883-4     Document Type: Article

References (32)

1. Marina N, Gebhardt M, Teot L et al (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422-441 (Pubitemid 39014554)
2. Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin North Am 44:973-989 (Pubitemid 27368674)
3. Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19:341-346 (Pubitemid 46883523)
4. Seibel NL, Krailo M, Chen Z et al (2007) Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943. Cancer 109:1646-1653 (Pubitemid 46595701)
5. Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 26:633-638 (Pubitemid 351264359)
6. Mintz MB, Sowers R, Brown KM et al (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65:1748-1754 (Pubitemid 40478600)
7. Miyamoto N, Higuchi Y, Mori K et al (2002) Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2:25-38 (Pubitemid 33086801)
8. Wittrant Y, Lamoureux F, Mori K et al (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 28:261-269
9. Coleman RE, Body JJ, Gralow JR et al (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 34(Suppl 1):S31-S42
10. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 19:420-432
11. Costa L, Lipton A, Coleman RE (2006) Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 3:143-153 (Pubitemid 44022751)
12. Dhillon S, Lyseng-Williamson KA (2008) Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 68:507-534 (Pubitemid 351342020)
13. Kohno N (2008) Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int J Clin Oncol 13:18-23
14. Lipton A (2008) Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(Suppl 1):S25-S30
15. Russell RG, Xia Z, Dunford JE et al (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 1117:209-257 (Pubitemid 350191297)
16. Ashton JA, Farese JP, Milner RJ et al (2005) Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 66:885-891 (Pubitemid 40812684)
17. Cheng YY, Huang L, Lee KM et al (2004) Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 42:410-415 (Pubitemid 38524469)
18. Ory B, Heymann MF, Kamijo A et al (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104:2522-2529 (Pubitemid 41691577)
19. Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:1075-1076 (Pubitemid 46376827)
20. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150-S162
21. Sparidans RW, Twiss IM, Talbot S (1998) Bisphosphonates in bone diseases. Pharm World Sci 20:206-213 (Pubitemid 28500182)
22. Marini JC (2003) Do bisphosphonates make children's bones better or brittle? N Engl J Med 349:423-442
23. Shaw NJ, Bishop NJ (2005) Bisphosphonate treatment of bone disease. Arch Dis Child 90:494-499 (Pubitemid 40627446)
24. Plotkin H, Rauch F, Zeitlin L et al (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88:4569-4575 (Pubitemid 37357495)
25. Mignogna MD, LoRusso L, Fedele S et al (2006) Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 24:1475-1477 (Pubitemid 46622016)
26. Phal PM, Myall RW, Assael LA et al (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR 28:1139-1145 (Pubitemid 46984558)
27. Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226-229 (Pubitemid 36700932)
28. Grissom LE, Kecskemethy HH, Bachrach SJ et al (2005) Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol 35:511-517 (Pubitemid 41166689)
29. Rauch F, Cornibert S, Cheung M et al (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821-827 (Pubitemid 46386546)
30. Whyte MP, Wenkert D, Clements KL et al (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463 (Pubitemid 36910024)
31. van van Persijn Meerten EL, Kroon HM, Papapoulos SE (1992) Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-254
32. Ward K, Cowell CT, Little DG (2005) Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 36:999-1002 (Pubitemid 40798000)